Summary of Adicet Bio (ACET) FY Conference Call - August 12, 2025 Company Overview - **Company**: Adicet Bio (ACET) - **Focus**: Leader in off-the-shelf gamma delta CAR T cell therapies, particularly for autoimmune diseases and solid tumors [3][4] Core Points and Arguments Allogeneic Approach - Adicet's gamma delta CAR T cell therapies are off-the-shelf, providing a differentiated safety profile compared to autologous therapies [4][8] - The ability to dose in outpatient settings is a significant advantage, especially for autoimmune diseases that often lead to organ damage [4][9] Autoimmune Disease Programs - Current programs include enrollment for systemic lupus erythematosus (SLE), lupus nephritis (LN), and systemic sclerosis [5][28] - The company is targeting CD20 instead of CD19 or CD22 due to its stable antigen presence on B cells, which has shown similar efficacy in B cell depletion [12][13] Safety and Efficacy - Gamma delta T cells have a lower frequency of cytokine release syndrome (CRS) and neurotoxicity compared to alpha beta T cells, allowing for safer outpatient administration [9][10] - The potential for patients to avoid prolonged immunosuppression before treatment is a key benefit of the allogeneic approach [17][18] Clinical Study Design - The lupus nephritis study is designed to enroll patients and report outcomes at various intervals, with a focus on safety and B cell depletion [29][39] - Initial readout expected to include at least six patients with three months of follow-up, assessing safety, immune reset, and renal function [38][40] Comparison of Study Types - Investigator-sponsored studies (ISTs) are more subjective and less rigorous compared to company-sponsored studies, which are multisite and have defined protocols [20][22] - Company-sponsored studies are viewed as more reliable for understanding patient benefits [23] Future Developments - The prostate cancer program (ADI 212) is in development, focusing on enhancing gamma delta T cell efficacy in solid tumors through gene editing and other technologies [45][46] - Manufacturing capabilities are robust, with a 14-day process and multiple sources for donor material, allowing for significant scalability [49][52] Important but Overlooked Content - The mean age of death for patients with SLE is 55, highlighting the urgent need for effective therapies that can reduce reliance on immunosuppressants and steroids [25] - The potential for patients to achieve immunosuppressant-free remission is a significant therapeutic goal, representing a major advancement in treatment [25][26] Conclusion Adicet Bio is positioned to make significant advancements in the treatment of autoimmune diseases and solid tumors through its innovative allogeneic gamma delta CAR T cell therapies, with ongoing clinical trials and a strong focus on safety and efficacy. The company’s approach addresses critical challenges in current therapies, particularly in terms of patient management and treatment accessibility.

Summary of Adicet Bio (ACET) Conference Call Company Overview - Adicet Bio is a leader in gamma delta CAR T cell therapies, which have several advantages over traditional therapies, including being off-the-shelf, better safety profiles, and effective tissue distribution [3][4][5][6][7]. Key Advantages of Gamma Delta CAR T Cells - **Off-the-Shelf Availability**: Gamma delta CAR T cells can be administered without prior patient-specific modifications, reducing preparation time [3]. - **Safety Profile**: These cells are associated with lower rates of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) compared to alpha beta T cells [4]. - **Tissue Distribution**: Gamma delta T cells effectively localize to tissues, which is beneficial for treating autoimmune diseases and solid tumors [5][6]. - **Innate Antitumor Activity**: They can target tumor cells even if they do not express the specific target, enhancing their therapeutic potential [7]. Clinical Programs and Data - Adicet Bio is currently running two clinical programs and has two preclinical programs in development [8]. - In clinical trials for diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), the complete response (CR) rates were comparable to autologous therapies, with a notable safety advantage [11][12]. - The company is focusing on autoimmune diseases, particularly lupus nephritis (LN) and systemic lupus erythematosus (SLE), with plans to expand to other conditions like systemic sclerosis and ANCA vasculitis [19][21]. Market Potential and Unmet Needs - The market for autoimmune diseases is significant, with high unmet medical needs, particularly in conditions like lupus nephritis, where patients face severe long-term health risks [25]. - The company aims to provide a one-time therapy that could lead to complete responses, reducing the need for ongoing immunosuppressants [25]. Data Expectations and Patient Selection - Investors are looking for data from at least six patients with three months of follow-up to assess efficacy [27]. - The ideal patient profile includes younger individuals with recent diagnoses and minimal existing tissue damage [31]. Competitive Landscape - The cell therapy space is competitive, with many companies pivoting from oncology to autoimmune diseases based on promising academic data [33]. - Adicet Bio differentiates itself by offering off-the-shelf therapies that do not require leukapheresis or personalized manufacturing, which can complicate treatment [36][39]. Future Developments - The company is also exploring renal cell carcinoma (RCC) as a new target, leveraging its unique advantages in tissue targeting and safety [44][46]. - Data from RCC trials is expected in the second half of the year, with a focus on achieving better outcomes than existing therapies [49]. Financial Position - Adicet Bio has approximately $150 million in cash, which is expected to fund operations into the second half of the following year [52]. - The company is open to business development opportunities to enhance its pipeline and financial stability [52]. Regulatory Environment - Interactions with regulatory agencies have been positive, with a collaborative approach noted in discussions about innovative therapies [53][54]. - The company believes that therapies demonstrating significant patient benefits will receive favorable attention from regulators [54]. Conclusion - Adicet Bio is positioned to make significant advancements in both autoimmune and oncology sectors with its gamma delta CAR T cell therapies, addressing critical unmet needs while navigating a competitive landscape and regulatory challenges [56].